UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
(Rule 13d-101)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED
PURSUANT
TO § 240.13d-1(a) AND AMENDMENTS THERETO
FILED PURSUANT TO
§ 240.13d-2(a)
(Amendment No. )*
Northwest Biotherapeutics, Inc.
(Name of Issuer)
Common Stock, $0.001 par value per share
(Title of Class of Securities)
66737P600
(CUSIP Number)
Woodford Investment Management LLP
9400 Garsington Road
Oxford OX4 2NH
United Kingdom
+44
(0)870 870 8482
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
June 9, 2015
(Date of Event Which Requires Filing of This
Statement)
If the filing person has previously filed a
statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because
of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ☒.
Note: Schedules filed in paper format
shall include a signed original and five copies of the schedule, including all exhibits. See § 240.13d-7 for other
parties to whom copies are to be sent.
_______________
* The remainder of this cover page shall be filled
out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent
amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of
this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934
(“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions
of the Act (however, see the Notes).
1 |
NAME OF REPORTING PERSONS
Woodford Investment Management LLP |
2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP(a) ☒
(b) ☐
|
3 |
SEC USE ONLY
|
4 |
SOURCE OF FUNDS
WC |
5 |
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEM 2(d) OR 2(e) ☐
|
6 |
CITIZENSHIP OR PLACE OF ORGANIZATION
United Kingdom |
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH |
7 |
SOLE VOTING POWER
0 |
8 |
SHARED VOTING POWER
19,671,392 shares of Common Stock |
9 |
SOLE DISPOSITIVE POWER
0 |
10 |
SHARED DISPOSITIVE POWER
20,461,392 shares of Common Stock |
11 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
20,461,392 shares of Common Stock |
12 |
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN
SHARES ☐
|
13 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
26.2% |
14 |
TYPE OF REPORTING PERSON
PN |
1 |
NAME OF REPORTING PERSONS
Neil Woodford |
2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP(a) ☒
(b) ☐
|
3 |
SEC USE ONLY
|
4 |
SOURCE OF FUNDS
Not applicable. |
5 |
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEM 2(d) OR 2(e) ☐
|
6 |
CITIZENSHIP OR PLACE OF ORGANIZATION
United Kingdom |
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH |
7 |
SOLE VOTING POWER
0 |
8 |
SHARED VOTING POWER
19,671,392 shares of Common Stock |
9 |
SOLE DISPOSITIVE POWER
0 |
10 |
SHARED DISPOSITIVE POWER
20,461,392 shares of Common Stock |
11 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
20,461,392 shares of Common Stock |
12 |
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN
SHARES ☐
|
13 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
26.2% |
14 |
TYPE OF REPORTING PERSON
IN |
Item 1. Security
and Issuer.
This statement relates
to the Common Stock, $0.001 par value per share (the “Shares”), of Northwest Biotherapeutics, Inc., a Delaware corporation
(the “Issuer”). The address of the principal executive offices of the Issuer is 4800 Montgomery Lane, Suite 800, Bethesda,
Maryland 20814.
Item 2. Identity
and Background.
(a) This statement
is being filed jointly by Woodford Investment Management LLP (the “Reporting Person”) and Neil Woodford, the Head of
Investment for the Reporting Person. The joint filing agreement of the Reporting Person and Mr. Woodford is attached as Exhibit
1 to this statement. The filers of this statement are collectively referred to herein as the “Group.”
(b) The principal
business address of the Reporting Person and Mr. Woodford is 9400 Garsington Road, Oxford OX4 2NH, United Kingdom.
(c) The Reporting
Person is an investment manager, authorized and regulated by the Financial Conduct Authority, in the business of investment management.
Mr. Woodford serves as the Head of Investment for the Reporting Person.
(d) Not applicable.
(e) Not applicable.
(f) The Reporting
Person and Mr. Woodford are citizens of the United Kingdom.
Item 3. Source and Amount
of Funds or Other Consideration.
To date, the Reporting
Person has expended a total of $149,641,997 to acquire 20,461,392 Shares. Such funds were provided from the Reporting Person’s
working capital on behalf of its clients.
Item 4. Purpose of Transaction.
The Reporting Person
acquired the securities of the Issuer based on its belief that the securities, when acquired, were undervalued and represented
an attractive investment opportunity. Depending upon overall market conditions, other investment opportunities available to the
Reporting Person, and the availability of securities of the Issuer at prices that would make the acquisition of additional securities
desirable, the Reporting Person may endeavor to increase its position in the Issuer through, among other things, the purchase of
securities of the Issuer on the open market or in private transactions or otherwise, on such terms and at such times as the Reporting
Person may deem advisable.
The Reporting Person
does not have any present plan or proposal which would relate to or result in any of the matters set forth in subparagraphs (a)
- (j) of Item 4 of Schedule 13D except as set forth herein or such as would occur upon completion of any of the actions discussed
herein.
Item 5. Interest in Securities
of the Issuer.
The percentages used
in this statement are calculated based upon 78,169,566 Shares outstanding as of August 7, 2015, as set forth in the Issuer’s
most recent Quarterly Report on Form 10-Q, filed with the SEC on August 10, 2015. All acquisitions or dispositions of Shares reported
herein were either purchases or sales, as the case may be, which were made in open-market transactions.
(A) The Reporting
Person
(a) As of the
close of business on the date hereof, the Reporting Person may be deemed to beneficially own 20,461,392 Shares, or 26.2% of the
issued and outstanding Shares.
(b) The Reporting
Person shares with Mr. Woodford the power to dispose of 20,461,392 Shares and to vote 19,671,392 Shares.
(c) Within the past 60 days, the Reporting Person
has purchased Shares as follows:
Date | |
Number
of
Shares Purchased | | |
Price Per Share | | |
Total Purchase Price | |
8/27/15 | |
| 150,000 | | |
$ | 8.16 | | |
$ | 1,224,000 | |
8/26/15 | |
| 20,000 | | |
$ | 7.62 | | |
$ | 152,400 | |
8/25/15 | |
| 100,000 | | |
$ | 7.85 | | |
$ | 785,000 | |
8/21/15 | |
| 500,000 | | |
$ | 7.60 | | |
$ | 3,800,000 | |
8/20/15 | |
| 100,000 | | |
$ | 9.03 | | |
$ | 903,000 | |
8/19/15 | |
| 150,000 | | |
$ | 9.29 | | |
$ | 1,393,500 | |
8/18/15 | |
| 100,000 | | |
$ | 9.55 | | |
$ | 955,000 | |
8/14/15 | |
| 100,000 | | |
$ | 9.63 | | |
$ | 963,000 | |
8/12/15 | |
| 25,000 | | |
$ | 9.84 | | |
$ | 246,000 | |
8/11/15 | |
| 125,000 | | |
$ | 9.98 | | |
$ | 1,247,500 | |
8/11/15 | |
| 17,938 | | |
$ | 9.96 | | |
$ | 178,662 | |
8/7/15 | |
| 82,062 | | |
$ | 9.92 | | |
$ | 814,055 | |
8/6/15 | |
| 100,000 | | |
$ | 10.51 | | |
$ | 1,051,000 | |
7/30/15 | |
| 100,000 | | |
$ | 11.31 | | |
$ | 1,131,000 | |
7/29/15 | |
| 13,522 | | |
$ | 11.91 | | |
$ | 161,047 | |
7/28/15 | |
| 84,478 | | |
$ | 11.86 | | |
$ | 1,001,909 | |
7/28/15 | |
| 26,800 | | |
$ | 11.06 | | |
$ | 296,408 | |
7/27/15 | |
| 173,200 | | |
$ | 11.02 | | |
$ | 1,908,664 | |
7/22/15 | |
| 20,000 | | |
$ | 11.96 | | |
$ | 239,200 | |
7/22/15 | |
| 100,000 | | |
$ | 11.96 | | |
$ | 1,196,000 | |
7/20/15 | |
| 100,000 | | |
$ | 11.96 | | |
$ | 1,196,000 | |
7/17/15 | |
| 71,723 | | |
$ | 11.88 | | |
$ | 852,069 | |
(d) The clients of the
Reporting Person, including managed accounts, have the right to receive or power to direct the receipt of dividends from, and the
proceeds from the sale of, the securities reported herein.
(B) Neil Woodford
(a) As of the
close of business on the date hereof, Mr. Woodford, by virtue of acting as Head of Investments for the Reporting Person, may be
deemed to beneficially own 20,461,392 Shares, or 26.2% of the issued and outstanding Shares. Mr. Woodford expressly disclaims beneficial
ownership of the Shares beneficially owned by the Reporting Person, except to the extent of any pecuniary interest therein.
(b) Mr. Woodford
shares with the Reporting Person the power to dispose of 20,461,392 Shares and to vote 19,671,392 Shares.
(c) Mr. Woodford
has made no purchases or sales of Shares.
Item 6. Contracts,
Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.
Other than the joint
filing agreement filed as Exhibit 1 to this statement, there are no contracts, arrangements, understandings or relationships between
the persons named in Item 2 hereof and between such persons and any person with respect to any securities of the Issuer, including
but not limited to transfer or voting of any of the securities, finders’ fees, joint ventures, loan or option arrangements,
puts or calls, guarantees of profits, divisions of profits or losses, or the giving or withholding of proxies.
See Item 2 above
regarding disclosure of the relationship between members of the Group, which disclosure is incorporated herein by reference.
Item 7. Material
to be Filed as Exhibits.
Exhibit No. | |
Description |
1 | |
Joint Filing Agreement, dated September 16, 2015 |
SIGNATURES
After reasonable
inquiry and to the best of our knowledge and belief, the undersigned certify that the information set forth in this statement is
true, complete and correct.
Dated: September 16, 2015
|
WOODFORD INVESTMENT MANAGEMENT LLP |
|
|
|
|
By: |
/s/ Simon Osborne |
|
|
Name: Simon Osborne |
|
|
Title: Head of Compliance and |
|
|
Authorized Signatory |
|
|
|
|
|
/s/ Neil Woodford |
|
|
Neil Woodford |
EXHIBIT 1
JOINT FILING AGREEMENT
In accordance with Rule
13d-1(k) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of
each of them of a statement on Schedule 13D (including amendments thereto) with respect to the Common Stock of the Issuer and further
agree that this Joint Filing Agreement be included as an Exhibit to such joint filings.
Dated: September 16, 2015
|
WOODFORD INVESTMENT MANAGEMENT LLP |
|
|
|
|
By: |
/s/ Simon Osborne |
|
|
Name: Simon Osborne |
|
|
Title: Head of Compliance and |
|
|
Authorized Signatory |
|
|
|
|
|
/s/ Neil Woodford |
|
|
Neil Woodford |
Northwest Biotherapeutics (QB) (USOTC:NWBO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Northwest Biotherapeutics (QB) (USOTC:NWBO)
Historical Stock Chart
From Apr 2023 to Apr 2024